- Histologically confirmed advanced lung adenocarcinoma with EGFR-sensitizing somatic mutations or a germline T790M mutation and no prior EGFR tyrosine kinase inhibitor (TKI) therapy or progressive disease after 1st or 2nd generation EGFR TKI therapy harboring somatic T790M mutation or patients with progressive disease after treatment with osimertinib who are eligible for local ablative therapy.